Hans van Houte sold $52k of NRIX
Chief Financial Officer at Nurix Therapeutics, Inc.. 4,304 shares at an average of $12.01, traded Jul 30, 2025, filed Jul 30, 2025.
Score components
- +22RoleCFO
- +7Trade size$52k at market
- 0Share of holdings soldSold 9.5% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -21.4%, 3m -1.5%, 6m +50.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001549595-25-000101, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 30, 2025 | MOption exercise Common Stock | +2,886 | $0.00 | $0 | 36,610 | Jul 30, 2025 |
| Jul 30, 2025 | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 38,610 | Jul 30, 2025 |
| Jul 30, 2025 | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 42,360 | Jul 30, 2025 |
| Jul 30, 2025 | MOption exercise Common Stock | +2,858 | $0.00 | $0 | 45,218 | Jul 30, 2025 |
| Jul 30, 2025 | SOpen-market sale Common Stock | -4,304 | $12.01 | $52k | 40,914 | Jul 30, 2025 |
| Jul 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,886 | $0.00 | $0 | 5,773 | Jul 30, 2025 |
| Jul 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 6,000 | Jul 30, 2025 |
| Jul 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 26,250 | Jul 30, 2025 |
| Jul 30, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,858 | $0.00 | $0 | 31,442 | Jul 30, 2025 |
Related signals
Other insiders at Nurix Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $134k 5,786 shares | -39% | |
| 9Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $149k 5,787 shares | -39% | |
| 0Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $37k 1,452 shares | -1% | |
| 5Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $108k 5,394 shares | -4% | |
| 7Weak | NRIXsell Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $53k 3,214 shares | -3% | |
| 11Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $126k 8,148 shares | -19% | |
| 33Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $238k 14,261 shares | -25% | |
| 24Weak | Nurix Therapeutics, Inc. | Gwenn Hansen Chief Scientific Officer | $81k 4,895 shares | -6% | |
| 23Weak | Nurix Therapeutics, Inc. | Christine Ring Chief Legal Officer | $73k 4,421 shares | -7% | |
| 29Weak | Nurix Therapeutics, Inc. | Hans van Houte Chief Financial Officer | $61k 3,661 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.